The manufacturer that remains after the Solventum health-care split is no longer a sleepy conglomerate waiting for litigation to fade. It is a three-segment industrial group whose second-quarter print finally showed the commercial-excellence program converting into volume, not just cost takeout. Organic growth at the adjusted level reached 5.4 percent. That pace more than doubled the prior-quarter crawl and forced a raise in full-year earnings guidance. The debate is no longer whether the factory can get leaner. It is whether the industrial engine can keep growing while PFAS and Combat Arms cash still leave on a published multi-year schedule.
Safety and Industrial did the heavy lifting, with organic sales up 8.2 percent and operating margin near twenty-eight percent. Transportation and Electronics converted backlog in semiconductors, aerospace, and data-center films. Consumer was the leak: retailer destocking in late June pulled the segment down even as store-level demand held up. The equity now prices a mid-teens-plus forward multiple on raised earnings. That multiple only holds if the two industrial groups, which already account for most of sales, keep outgrowing their end markets rather than merely riding an easy compare.
GAAP earnings rose on a Solventum mark-to-market gain that almost exactly offset a large loss on the Dyneon fluoropolymer sale. Adjusted free cash flow of $1.3 billion funded a $1 billion repurchase plus the ordinary dividend. The next year decides whether mid-single-digit organic growth and a mid-twenties operating margin can coexist with a still-heavy settlement calendar.